Skip to main content

Table 1 Baseline socio-demographics of participants

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

Characteristics Arm 1:
HCQ + SOC
Arm 2:
SOC alone
Total
Total randomized and analyzed 55 50 105
Age in years    
Median (IQR) 30 (26–44) 32 (27–42) 32 (27–43)
Range 18–64 20–59 18–64
Age categories, n (%)    
18–34 29 (52.7) 28 (56.0) 57 (54.3)
35–59 25 (45.5) 22 (44.0) 47 (44.8)
 ≥ 60 1 (1.8) 0 1 (0.9)
Sex, n (%)    
Male 39 (70.9) 37 (74.0) 76 (72.4)
Female 16 (29.1) 13 (26.0) 29 (27.6)
Baseline SARS COV-2 CT-valuesa    
Number of observations 17 17 34
Mean (SD) 19.0 (5.1) 18.9 (4.9) 18.9 (4.9)
Median (IQR) 18.8 (16.1–23.0) 19.9 (14.8–22.4) 19.6 (14.8–23.0)
Range (minimum–maximum) 9.6–27.1 9.6–25.5 9.6–27.1
Comorbidity, n (%)    
High blood pressureb 2 (3.6) 1 (2.1) 3 (2.9)
Heart disease 1 (1.8) 0 1 (0.9)
Diabetesb 2 (3.5) 1 (2.0) 3 (2.8)
Cigarette smokingb 2 (3.6) 0 2 (1.9)
Alcohol dependencyb 7 (12.3) 6 (12.5) 13 (12.4)
HIV positiveb 3 (5.4) 2 (4.1) 5 (4.8)
  1. HCQ hydroxychloroquine, SOC standard of care, SD standard deviation, IQR Inter-quartile range
  2. aThe baseline SARS COV-2 CT-values were defined as the CT-values measured at patient’s enrolment. However, some participants had missing CT values at enrolment because majority of participants reported 4 days after their first positive PCR tests, and the repeat PCR test at enrolment for most of them was negative, as highlighted in this table. Only positive PCR tests could have SARS COV-2 CT-values
  3. bMissing values: High blood pressure (n = 2), Heart disease (n = 1), Diabetes (n = 1), Cigarette smoking (n = 2), Alcohol dependency (n = 2), HIV status (n = 1), History of allergies (n = 1), Medication before admission (n = 1)